TribLIVE

| USWorld

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

New stroke treatment no more effective than the current one

Email Newsletters

Click here to sign up for one of our email newsletters.

Daily Photo Galleries

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

By The Washington Post
Friday, Feb. 8, 2013, 6:14 p.m.
 

Three long-awaited studies have shown that mechanically removing a blood clot from a stroke patient's brain is no more useful than the older treatment of giving an IV dose of a clot-dissolving drug to the whole body.

The results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians. Many had already adopted the more aggressive strategy over the last decade.

“For the stroke field this is a really big deal,” Walter Koroshetz, deputy director of the National Institute of Neurological Disorders and Stroke, said of the findings, which were presented over three days at the International Stroke Conference in Honolulu.

The institute paid for two of the trials, one of which cost $27 million. One study took eight years to complete because it was so difficult to enroll patients willing to take the chance they'd be randomly assigned to get the older treatment.

Practitioners hoped that “endovascular treatment,” in which a catheter is threaded into a blocked artery and the clot pulled out, would do for stroke patients what it has done for heart attack patients. In them, going after clots with angioplasty balloons and stents is clearly more effective than giving clot-dissolving drugs through a vein in the arm.

“We did this study with the strong expectation that we would find a positive benefit. We were surprised,” said Joseph P. Broderick of the University of Cincinnati Neuroscience Institute, who headed one of the studies.

His view was echoed by Alfonso Ciccone, a neurologist from Milan who led a clinical trial in Italy: “We were surprised. We wanted the superiority of endovascular treatment.”

Insurance companies and Medicare, the health insurer for the elderly, already cover the endovascular procedure. It costs about $23,000 compared to $11,000 for acute stroke treatment using intravenous clot-dissolving (“thrombolytic”) drugs.

Further, many practitioners believe that newer clot-retrieving devices work better than the ones used in the three trials. Because endovascular procedures were shown to be no more dangerous than IV thrombolytics, physicians may continue to perform it and assume the outcomes can only get better.

“Will it change practice? That's a good question,” said Koroshetz. “The payers may look at this and wonder if they should continue paying for these procedures. If it gets to that point, then clearly things will change.”

Stroke is the fourth-leading cause of death.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Nation

  1. Name of cop withheld in shooting of motorist in South Carolina
  2. 2 women advance to final phase of Army Ranger training
  3. Food industry players fighting proposed dietary guidelines drop millions on lobbyists
  4. Pressure mounts for Biden to join 2016 White House race
  5. U.S., Hong Kong researchers develop computer model to examine spread of influenza
  6. State Department accuses top Clinton aide of violations
  7. 4 dead, 65 sickened in Bronx by Legionella
  8. ‘Fast, Furious’ pistol was sold to gunman in foiled Texas terrorist attack
  9. Marines finally ready to roll out controversial fighter jet
  10. Construction of giant bridges sparks curiosity, high demand for public tours
  11. Obama’s nuclear deal lobbying sways Democrats